Literature DB >> 18989650

[Cholestasis and liver dysfunction in critical care patients].

M Kredel1, J Brederlau, N Roewer, C Wunder.   

Abstract

Cornerstones of the diagnostic investigations of disturbances in liver function are analysis and sophisticated evaluation of serum liver enzymes, bilirubin and ammonia. Coagulation factors, serum albumin and cholinesterase levels are indicators of the hepatic metabolic capacity. Dynamic assessment of complex liver functions allows quantification of the hepatic metabolic activity and excretory function. Imaging techniques permit visualization of the size and texture of the liver, the vascular supply and perfusion as well as an assessment of the gall bladder and the extra-hepatic and intra-hepatic bile ducts. Manifold causes for cholestasis and/or liver dysfunction are known, such as ventilation with high pressure, total parenteral nutrition, shock, hypoxia and certain drugs. Obstructive cholestasis requires reconstitution of bile duct drainage, while non-obstructive cholestasis primarily requires treatment of the causative disease. The symptomatic therapy of liver insufficiency is rarely possible via direct treatment of the cause, but mostly requires specific management of secondary organ dysfunctions related to hepatic dysfunction including circulatory failure, hepatorenal syndrome and hepatic encephalopathy. In rare cases a temporary liver surrogate is necessary. The molecular absorbent recirculating system (MARS), a form of extracorporeal albumin dialysis, is introduced as a modality for the treatment of liver failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18989650     DOI: 10.1007/s00101-008-1459-y

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  65 in total

1.  MR versus multislice CT cholangiography in evaluating patients with obstruction of the biliary tract.

Authors:  F Zandrino; P Curone; L Benzi; M L Ferretti; F Musante
Journal:  Abdom Imaging       Date:  2004-11-17

Review 2.  Hepatitis B: the pathway to recovery through treatment.

Authors:  F Blaine Hollinger; Daryl T-Y Lau
Journal:  Gastroenterol Clin North Am       Date:  2006-12       Impact factor: 3.806

Review 3.  Brain edema in acute liver failure: can it be prevented? Can it be treated?

Authors:  Andres T Blei
Journal:  J Hepatol       Date:  2007-02-05       Impact factor: 25.083

4.  Which patients benefit from hemodialysis therapy in hepatorenal syndrome?

Authors:  Oliver Witzke; Markus Baumann; Daniel Patschan; Susann Patschan; Anna Mitchell; Ulrich Treichel; Guido Gerken; Thomas Philipp; Andreas Kribben
Journal:  J Gastroenterol Hepatol       Date:  2004-12       Impact factor: 4.029

5.  The 1995 Ciba-Geigy Award Lecture. Intrinsic regulation of hepatic blood flow.

Authors:  W W Lautt
Journal:  Can J Physiol Pharmacol       Date:  1996-03       Impact factor: 2.273

6.  Plasma disappearance rate of indocyanine green in liver dysfunction.

Authors:  P Faybik; H Hetz
Journal:  Transplant Proc       Date:  2006-04       Impact factor: 1.066

Review 7.  Clinical use of serum enzymes in liver disease.

Authors:  J J Reichling; M M Kaplan
Journal:  Dig Dis Sci       Date:  1988-12       Impact factor: 3.199

8.  Effects of dobutamine on gastric mucosal perfusion and hepatic metabolism in patients with septic shock.

Authors:  L M Joly; M Monchi; A Cariou; J D Chiche; F Bellenfant; F Brunet; J F Dhainaut
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

9.  Hepatic dysfunction increases length of stay and risk of death after injury.

Authors:  Brian G Harbrecht; Mazen S Zenati; Howard R Doyle; John McMichael; Ricard N Townsend; Keith D Clancy; Andrew B Peitzman
Journal:  J Trauma       Date:  2002-09

10.  Lignocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients.

Authors:  J Schröter; C Wandel; H Böhrer; H Schmidt; B W Böttiger; E Martin
Journal:  Anaesthesia       Date:  1995-10       Impact factor: 6.955

View more
  1 in total

1.  [Secondary sclerosing cholangitis after multiple trauma and long-term intensive care treatment: case report of a characteristic course].

Authors:  M Seemann; G Kirchner; S Bele; B Sinner; B Graf; M Kieninger
Journal:  Anaesthesist       Date:  2013-01-24       Impact factor: 1.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.